X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (39) 39
male (32) 32
middle aged (32) 32
female (31) 31
gastroenterology & hepatology (23) 23
adult (20) 20
aged (17) 17
gastroenterology and hepatology (14) 14
index medicus (11) 11
liver cirrhosis - physiopathology (10) 10
cirrhosis (8) 8
double-blind method (8) 8
drug therapy, combination (8) 8
hepatitis c (8) 8
hepatitis c, chronic - drug therapy (8) 8
liver cirrhosis (7) 7
liver cirrhosis - complications (7) 7
treatment outcome (7) 7
hemodynamics - drug effects (6) 6
hepacivirus - genetics (6) 6
hepatitis c, chronic - virology (6) 6
hypertension (6) 6
interferon (6) 6
prospective studies (6) 6
recombinant proteins (6) 6
risk factors (6) 6
ascites (5) 5
interferon-alpha - administration & dosage (5) 5
liver cirrhosis - drug therapy (5) 5
liver-disease (5) 5
polyethylene glycols - administration & dosage (5) 5
rna, viral - blood (5) 5
spontaneous bacterial peritonitis (5) 5
abridged index medicus (4) 4
administration, oral (4) 4
adolescent (4) 4
antiviral agents - administration & dosage (4) 4
antiviral agents - adverse effects (4) 4
antiviral agents - therapeutic use (4) 4
cirrhotic-patients (4) 4
drug therapy (4) 4
genotype (4) 4
interferon-alpha - adverse effects (4) 4
interferon-alpha - therapeutic use (4) 4
liver cirrhosis - therapy (4) 4
paracentesis (4) 4
polyethylene glycols - adverse effects (4) 4
portal system - drug effects (4) 4
pressure (4) 4
prevention (4) 4
prognosis (4) 4
ribavirin (4) 4
ribavirin - administration & dosage (4) 4
therapy (4) 4
young adult (4) 4
anti-infective agents - therapeutic use (3) 3
ascites - therapy (3) 3
bilirubin - blood (3) 3
care and treatment (3) 3
cholestasis (3) 3
ciprofloxacin - therapeutic use (3) 3
clinical trials (3) 3
drug administration schedule (3) 3
esophageal and gastric varices - physiopathology (3) 3
fibrosis (3) 3
genetic aspects (3) 3
genotype & phenotype (3) 3
genotypes (3) 3
health aspects (3) 3
hemorrhage (3) 3
hepacivirus - isolation & purification (3) 3
infections (3) 3
intravenous albumin (3) 3
liver cirrhosis - diagnosis (3) 3
multivariate analysis (3) 3
patient outcomes (3) 3
peritonitis (3) 3
peritonitis - mortality (3) 3
polyethylene glycols - therapeutic use (3) 3
propranolol (3) 3
pruritus (3) 3
recurrence (3) 3
splanchnic circulation - drug effects (3) 3
treatment failure (3) 3
viral load (3) 3
virus-infection (3) 3
albumin (2) 2
alcoholic cirrhosis (2) 2
alkaline phosphatase - blood (2) 2
analysis (2) 2
analysis of variance (2) 2
anemia (2) 2
antigens - analysis (2) 2
argentina (2) 2
argentina - epidemiology (2) 2
ascitic fluid - microbiology (2) 2
bacterial infections - mortality (2) 2
biological response modifiers (2) 2
biopsy (2) 2
boceprevir (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2405 - 2416
In patients with HCV infection and no previous treatment, the addition of telaprevir to peginterferon–ribavirin resulted in higher response rates than those... 
GENETIC-VARIATION | IL28B | MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | GENOTYPE-1 PATIENTS | PEGINTERFERON ALPHA-2B | AMERICAN PATIENTS | ALPHA-2B PLUS RIBAVIRIN | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2b | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Fees & charges | Antiretroviral drugs | Liver diseases | Clinical trials | Chronic infection | Employees | Infections | Proteinase inhibitors | Genomes | Ribonucleic acid--RNA | Patients | Ribavirin | Liver cancer | Genotype & phenotype | Hepatitis | Skin | Interferon | Genotypes | Pharmaceuticals
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2417 - 2428
Journal Article
Hepatology, ISSN 0270-9139, 01/2013, Volume 57, Issue 1, pp. 411 - 413
Journal Article
Gastroenterology, ISSN 0016-5085, 2009, Volume 136, Issue 5, pp. 1618 - 1628.e2
Journal Article
JAMA, The Journal of the American Medical Association, ISSN 0098-7484, 02/2003, Volume 289, Issue 8, p. 964
Journal Article
Gastroenterology, ISSN 0016-5085, 2011, Volume 140, Issue 7, pp. 1990 - 1999
Background & Aims Several studies have reported that low doses of interferon can delay the development of hepatocellular carcinoma (HCC) and progression of... 
Gastroenterology and Hepatology | Liver Cancer | Clinical Trial | Evaluation of PegIntron in Control of Hepatitis C Cirrhosis Program | EPIC 3 Program | TRIAL | EPIC3 Program | INTERFERON-ALPHA | VIRUS | RETROSPECTIVE COHORT | GASTROENTEROLOGY & HEPATOLOGY | South America | Carcinoma, Hepatocellular - mortality | Prospective Studies | Carcinoma, Hepatocellular - prevention & control | Humans | Middle Aged | Liver Cirrhosis - mortality | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Recombinant Proteins | Liver Neoplasms - mortality | Hepatitis C, Chronic - mortality | North America | Viral Load | Patient Selection | Time Factors | Female | Hypertension, Portal - virology | Liver Neoplasms - prevention & control | Liver Neoplasms - virology | Liver Cirrhosis - drug therapy | Liver Cirrhosis - diagnosis | Drug Administration Schedule | Risk Assessment | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Carcinoma, Hepatocellular - virology | Biomarkers - blood | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Disease Progression | Hypertension, Portal - drug therapy | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | Interferon-alpha - adverse effects | Medical colleges | Liver cancer | Care and treatment | Analysis | Development and progression | Interferon | Hepatoma | Colchicine | Biological response modifiers | Hepatitis C | Liver cirrhosis
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 61, Issue 6, pp. 1220 - 1227
Journal Article
Journal Article
by Zeuzem, S and Flisiak, R and Vierling, J. M and Mazur, W and Mazzella, G and Thongsawat, S and Abdurakhmanov, D and Van Kính, N and Calistru, P and Heo, J and Stanciu, C and Gould, M and Makara, M and Hsu, S.‐J and Buggisch, P and Samuel, D and Mutimer, D and Nault, B and Merz, M and Bao, W and Griffel, L. H and Brass, C and Naoumov, N. V and Tanno, Hugo and Bessone, Fernando and Terg, Ruben and Frider, Bernardo and Bertuzzi, Romina and Desmond, Paul and Zekry, Amany and Weltman, Martin and George, Jacob and Crawford, Darrell and Matthews, Gail and Moreno, Christophe and Vlierberghe, Hans and Reynaert, Hendrik and Gould, Michael and Lee, Samuel and Ramji, Alnoor and Tam, Edward and Marotta, Paul and Yoshida, Eric and Wong, Florence and Feld, Jordan and Samuel, Didier and Marcellin, Patrick and Alric, Laurent and Zarski, Jean‐Pierre and Zoulim, Fabien and Buggisch, Peter and Hinrichsen, Holger and Goeser, Tobias and Zeuzem, Stefan and Galle, Peter and Berg, Thomas and Schott, Eckart and Rasenack, Jens and Gerken, Guido and Wedemeyer, Hans and Tsang, Owen and Yuen, Man‐Fung and Chan, Henry and Hui, Aric Josun and Makara, Mihaly and Tornai, Istvan and Gervain, Judit and Szalay, Ferenc and Varga, Marta and Horvath, Gabor and Hunyady, Bela and Vincze, Aron and Mazzella, Giuseppe and Gaeta, Giovanni Battista and Alberti, Alfredo and Colombo, Massimo and Andreone, Pietro and Rizzetto, Mario and Angelico, Mario and Craxi, Antonio and Picciotto, Antonino and Sacchi, Paolo and Vinci, Maria and Invernizzi, Pietro and Bruno, Savino and Heo, Jeong and Lee, Younjae and Cho, Mong and Han, Sangyoung and Lee, Jinwoo and Ahn, Sanghoon and Lim, Youngsuk and Hwang, Seonggyu and Sanchez, Juan and Muñoz, Linda and Maldonado, Hector and Mazur, Wlodzimierz and Flisiak, Robert and Jablkowski, Maciej and Kryczka, Wieslaw and ... and ESSENTIAL II Study Grp and ESSENTIAL II Study Group and the ESSENTIAL II Study Group
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 10/2015, Volume 42, Issue 7, pp. 829 - 844
Summary Background Alisporivir (ALV) is an oral, host‐targeting agent with pangenotypic anti‐hepatitis C virus (HCV) activity and a high barrier to resistance.... 
PLUS RIBAVIRIN | CYCLOPHILIN INHIBITOR | VIRUS-INFECTION | ANTIVIRAL TREATMENT | CHRONIC HEPATITIS-C | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | INTERFERON-ALPHA 2A | LIVER-DISEASE | GASTROENTEROLOGY & HEPATOLOGY | INDUCED PANCREATITIS | DEBIO 025 | United States | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Young Adult | Ribavirin - administration & dosage | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Double-Blind Method | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Cyclosporine - adverse effects | Adolescent | Cyclosporine - administration & dosage | Aged | Interferon-alpha - adverse effects | Hypertension | Thrombocytopenia | Therapy | Anemia | Pancreatitis | Chronic infection | Clinical trials | Viruses | Infections | Patients | Ribavirin | Cirrhosis | Disease resistance | Hepatitis | Genotype & phenotype | Randomization | Interferon | Hepatitis C virus | Hepatitis C | Genotypes
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2011, Volume 54, Issue 2, pp. 227 - 235
EPIC-3 is a prospective, international study that has demonstrated the efficacy of PEG-IFN alfa-2b plus weight-based ribavirin in patients with chronic... 
Cirrhosis | Relapser | Fibrosis | Biomarkers | Non-responder | Treatment failure | Early virologic response | Hepatitis C
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2010, Volume 54, Issue 2, pp. 227 - 235
Journal Article